A survival prognostic model for high-risk myelodysplastic syndrome patients treated with decitabine

Key Points

• The aim is to create a survival prognostic model for patients with high-risk myelodysplastic syndrome (MDS) receiving decitabine.
• Analysis of clinical variables, including age and bone marrow blasts.
• Evaluation of cytogenetic and mutational factors.
• Development of a prognostic model incorporating these variables.
• Identified key factors affecting prognosis, such as age and cytogenetics.
• The model may improve individualized treatment strategies for high-risk MDS patients.

Abstract